JasonRomancikMD

Hematology • Atlanta, GA

Hematologic Oncology

Physician

Join to view full profile

Dr. Romancik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Romancik's full profile

Already have an account?

Office
1365 Clifton Rd NE Bldg B
Atlanta, GA 30322
Phone+1 404-712-1722

Fax+1 404-251-1899

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2018 - 2021
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2015 - 2018
Rush Medical College of Rush University Medical CenterClass of 2015

Certifications & Licensure

GA State Medical License 2021 - 2026
MO State Medical License 2015 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
Haematologica. 2024-11-14
1 citations
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq
Blood Advances. 2024-08-27
3 citations
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason Romancik, Pamela Allen
Blood Advances. 2024-05-28

Abstracts/Posters

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Jason Romancik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Jason Romancik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019